Results: 4

1.
Figure 2

Figure 2. From: Efficacy of Neoadjuvant Chemoradiation followed by Liver Transplantation for Perihilar Cholangiocarcinoma at 12 US Centers.

Cumulative drop-out rate in 3-month intervals from the end of chemoradiation (ie, time of listing).

Sarwa Darwish Murad, et al. Gastroenterology. ;143(1):10.1053/j.gastro.2012.04.008.
2.
Figure 1

Figure 1. From: Efficacy of Neoadjuvant Chemoradiation followed by Liver Transplantation for Perihilar Cholangiocarcinoma at 12 US Centers.

Flow chart of 287 patients with perihilar cholangiocarcinoma who underwent neoadjuvant therapy, staging surgery, and, finally, LT. The outer left boxes represent patients who dropped out from the protocol (total, 71 patients).

Sarwa Darwish Murad, et al. Gastroenterology. ;143(1):10.1053/j.gastro.2012.04.008.
3.

Figure 4. From: Efficacy of Neoadjuvant Chemoradiation followed by Liver Transplantation for Perihilar Cholangiocarcinoma at 12 US Centers.

Kaplan–Meier recurrence-free survival curves for (A) patients who are within UNOS/OPTN criteria for standard MELD exception (N = 166) vs those who are not (N = 48); and (B) patients with a mass larger than 3 cm (N = 23) vs 3 cm or smaller (N = 191).

Sarwa Darwish Murad, et al. Gastroenterology. ;143(1):10.1053/j.gastro.2012.04.008.
4.

Figure 3. From: Efficacy of Neoadjuvant Chemoradiation followed by Liver Transplantation for Perihilar Cholangiocarcinoma at 12 US Centers.

Kaplan–Meier curves for (A) intent-to-treat survival for the total population (N = 287); (B) recurrence-free survival for all transplanted patients (N = 214); (C) recurrence-free survival for deceased donor (N = 152) vs living donor (N = 52) liver transplantation; (D) recurrence-free survival for primary sclerosing cholangitis (N = 143) vs those without (N = 71); (E) intent-to-treat survival comparing center 1 (N = 193) vs all other centers (N = 94); and (F) recurrence-free survival comparing center 1 (N = 131) vs all other centers (N = 83). The 2-, 5-, and 10-year survival rates are shown as percentages (95% CI).

Sarwa Darwish Murad, et al. Gastroenterology. ;143(1):10.1053/j.gastro.2012.04.008.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk